existence of biosynthetic routes for the direct synthesis of free ADMA by methylation of free arginine. Free ADMA is formed exclusively by the sequence of methylation of arginine residues of proteins, followed by proteolysis of these proteins. There are two pathways for the clearance of ADMA from the cell. In the first, ADMA is enzymatically degraded by dimethylarginine dimethylaminohydrolase (DDAH), which cleaves ADMA into citrulline and dimethylamine. The second pathway consists of export of ADMA from the cell to the plasma via cationic amino acid transporters (CAT) in the plasma membrane. Likewise, clearance from the plasma compartment also occurs by two routes: renal excretion and uptake by cells via CAT. The activity of CAT is thus involved in both cellular release and uptake of ADMA, and as such plays an important role in intercellular and interorgan transport of ADMA. Both the kidney and the liver seem to be important organs in the clearance of ADMA from the plasma. The interorgan transport of ADMA may have serious consequences in diseases and clinical conditions that are associated with altered ADMA metabolism. If, in a particular organ, large amounts of ADMA are formed and subsequently exported to the plasma, this may lead to uptake of ADMA by other organs, which will affect their function.
The processes of protein methylation, proteolysis, degradation of ADMA by DDAH, intracellular traffic via amino acid transporters, and metabolism of ADMA at organ level are discussed in the following sections, with special emphasis on the regulation of these processes.
Protein methylation
Methylation of the amino acids lysine, histidine and arginine in proteins is a specific form of posttranslational modification used by cells to expand the functional repertoire of their proteome. The terminal guanidino group of arginine can be dimethylated by protein arginine methyltransferases (PRMTs), of which two classes exist. 5 Both classes of PRMT catalyze the monomethylation of arginine but, when a second methyl group is attached to monomethylarginine, the reaction product is PRMT dependent. Type 1 PRMTs catalyze the formation of ADMA, whereas type 2 PRMTs lead to the formation of symmetric dimethylarginine (SDMA). Both types of PRMT preferentially methylate arginine located in arginineglycine-rich sequences of proteins. 5 A recent proteomic analysis has identified more than 200 proteins that are putatively arginine methylated. 6 Many of these have strong interactions with nucleic acids and are involved in processes such as splicing of pre-mRNA, transcription, protein translation, and signal transduction. [5] [6] [7] [8] Arginine methylation is also involved in targeting proteins for nuclear import. 9
Regulation of methylation by S-adenosylmethionine and S-adenosylhomocysteine
All PRMTs use S-adenosylmethionine (SAM), which is synthesized from methionine and ATP, as the methyl group donor. After transfer of its methyl group, SAM is converted into S-adenosylhomocysteine (SAH). SAH is enzymatically converted into homocysteine, which is either metabolized in the trans-sulfuration route or remethylated to methionine. Because synthesis of ADMA requires the transfer of two methyl groups, two equivalents of homocysteine are formed as a byproduct. Several groups have investigated the link between the metabolic pathways of ADMA and homocysteine. A positive association between plasma levels of homocysteine and ADMA has been reported, 10 but this was not found in other studies. 11, 12 Oral methionine loading can be used to induce acute hyperhomocysteinemia. It is interesting that we and other investigators have observed a significant increase in plasma ADMA concentration after a methionine-loading test. [13] [14] [15] It is important to note that the enzymatic hydrolysis of SAH to homocysteine is reversible, with equilibrium dynamics that strongly favor SAH synthesis rather than hydrolysis. In situations where homocysteine is elevated, intracellular SAH levels may thus increase. Because SAH is a potent inhibitor of transmethylation reactions, its accumulation may lead to hypomethylation of macromolecules. 16 In accordance with this mechanism, DNA hypomethylation has been observed in hyperhomocysteinemic patients with end-stage renal disease. 17 It has also been shown that the production of ADMA by endothelial cells is inhibited by incubation with SAH. 18 Whether endogenous levels of SAM and SAH play an important role in the regulation of synthesis of ADMA is not clear at present, but this certainly deserves further investigation.
Stimulation of protein methylation by autoantibodies
Recent reports suggest a link between the occurrence of autoantibodies and protein methylation. Systemic lupus erythematosus (SLE) is a systemic inflammatory disease characterized by the presence of a host of autoantibodies, many of which recognize antigens from the cell nucleus. These autoantibodies play an important role in the pathogenesis and activity of SLE. Common antigenic targets include double-stranded DNA (dsDNA) and several ribonucleoproteins, including the spliceosomal complex. The autoantibodies specifically recognize the basic arginine-glycinerich domains of the proteins involved. 19 Notably, these domains are also preferred sites for the methylation of arginine residues by PRMTs. 5, 20 Indeed, several Arginine residues of proteins are methylated by protein arginine methyltransferases (PRMT). In this transmethylation process, S-adenosylmethionine (SAM), which serves as donor of the methyl group, is converted into S-adenosylhomocysteine (SAH). SAH is hydrolyzed to homocysteine, which can be remethylated to methionine. Free ADMA is formed on proteolysis of methylated proteins. Most ADMA is hydrolyzed by intracellular dimethylarginine dimethylaminohydrolase (DDAH) into citrulline and dimethylamine. Some ADMA is exported from the cell by cationic amino acid transporters (CAT). A small fraction of circulating ADMA is excreted by the kidneys, but most ADMA is taken up by other cells or organs and degraded by DDAH.
spliceosomal proteins have been shown to contain both ADMA and SDMA residues in their sequence. 8, 20 It was recently shown that autoantibodies to dsDNA cross-react with the arginine-glycine-rich domain of heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2). 21 In the presence of anti-dsDNA, methylation of hnRNP A2 by PRMT1 was increased in a dose-dependent manner to 3.5 times the control level. 21 Anti-dsDNA antibodies may therefore cause increased ADMA production by upregulating the dimethylation of arginine residues by PRMT1.
This mechanism of excess ADMA production possibly plays a role in the pathology of rheumatoid diseases such as SLE. Cardiovascular disease is an important cause of morbidity and mortality in patients with SLE, 22 but traditional Framingham risk factors fail fully to account for this excess of cardiovascular events. 23 In addition, the endothelial dysfunction associated with SLE cannot be explained by classic risk factors. 24 We have recently assessed the association between ADMA and cardiovascular disease in a cross-sectional study in 107 patients with SLE. 25 The prevalence of cardiovascular disease increased across tertiles of plasma ADMA concentrations (p ϭ 0.023). Most importantly, we observed a significant positive association between plasma ADMA concentrations and titres of anti-dsDNA autoantibodies (r ϭ 0.43; p Ͻ 0.001), corroborating the in vitro data described above. Anti-dsDNA autoantibodies have also been shown to stimulate the expression of pro-inflammatory cytokines by mononuclear cells 26 and we hypothesize that these antibodies play a dual role in the pathology of SLE by augmenting the inflammatory reaction and stimulating ADMA production ( Figure 2 ).
Reversibility of arginine methylation
The methylation of proteins is generally considered to be irreversible because demethylating enzymes in eukaryotic cells have been elusive. Recently, this paradigm has been challenged by the identification of an enzyme that can demethyliminate monomethylated arginine. 27 Two research groups have reported that peptidylarginine deiminase 4 (PAD4), which has a nuclear localization, is able to convert the monomethylated arginine present in histone proteins to citrulline by hydrolytic cleavage of the monomethylamine group. 28, 29 It should be noted that PAD4 does not seem to be able to deiminate ADMA 29 but, as monomethylarginine is an intermediate product in the synthesis of ADMA, its deimination by PAD4 interferes with the synthesis of ADMA. In a strict sense, this deimination reaction is not a reversal of arginine methylation because it produces citrulline instead of arginine.
The reaction described above may be considered an exception to the rule. In general, protein methylation is a one-way process and methylated arginine residues remain an integral part of the protein until it is degraded by proteolysis.
Proteolysis of methylated proteins
Proteolysis of methylated proteins is the process that leads directly to the liberation of free ADMA, which, in contrast to protein-bound ADMA, serves as a competitive inhibitor of NOS. Protein synthesis and proteolysis are the anabolic and catabolic counterparts of protein turnover, respectively. Under physiological conditions, where no net protein synthesis or degradation occurs, both aspects are in balance. Proteolysis ultimately results in the complete degradation of proteins down to the level of free amino acids, which are re-utilized for de novo synthesis of proteins. Amino acids that have been modified by post-translational processes cannot be re-utilized for protein synthesis and are either excreted or metabolized. Whole-body protein turnover has been estimated at 300 g/day. 30 Individual proteins are destroyed at widely differing rates, with half-life times ranging from several minutes to many years. 31 It is very likely that the turnover of methylated proteins occurs at a high rate.
In contrast to other post-translational protein modifications that are reversible, such as phosphorylation, arginine methylation is virtually irreversible. This implies that, if arginine methylation is considered as a switch that turns on a particular function of a protein, the only means to switch off that function is by degrading the methylated protein and replacing it by a newly synthesized unmethylated copy.
Rapid in vitro proteolysis of methylated proteins
We have obtained experimental in vitro evidence that proteins containing methylated arginine are degraded at a very high rate. Incubation of a homogenate of rat kidney at 37ЊC resulted in a very rapid release of free ADMA, which was subsequently degraded by DDAH ( Figure 3A ). If ADMA degradation was prevented by blocking the activity of DDAH, free ADMA accumulated to a much higher concentration. Comparison with total ADMA (i.e. the sum of free and proteinbound ADMA, measured after acid hydrolysis) revealed that 66% of the protein-bound ADMA was released after 60 minutes ( Figure 3B ). The amount of protein-bound SDMA was approximately six-fold lower in comparison with protein-bound ADMA, but, in agreement with the data on ADMA, proteolysis resulted in the liberation of more than 60% of SDMA after 60 minutes ( Figure 3C ). In contrast, the release of protein-bound arginine occurred at a much lower rate, and was less than 8% at the end of the incubation period ( Figure 3D ). Although the conditions used in this experiment were unphysiological, it shows convincingly that the proteolytic machinery of the cell has the capacity to degrade methylated proteins at a very high rate.
Potential role of the proteasome
We can only speculate on the mechanisms involved in the accelerated proteolysis of proteins containing methylated arginine residues. Most intracellular proteins are degraded by the proteasome, which serves as a quality-control system by rapidly degrading misfolded and damaged proteins, whose accumulation would otherwise interfere with normal cellular function. 31, 32 The 26S proteasome is a large multiprotein complex, consisting of a barrel-shaped core with combined tryptic, chymotryptic and caspase-like protease activities (the 20S proteasome), which is capped at the ends by 19S regulatory complexes. In contrast to simple proteolytic enzymes, which cut their substrate at a single spot in a scissor-like fashion, the proteasome acts more like a shredder that in a single pass cuts a protein molecule into a large number of peptides. Proteins destined for degradation by the proteasome are conjugated to ubiquitine, which serves as a recognition signal for the regulatory subunits of the 26S proteasome. However, there are strong indications that proteins damaged by oxidative processes do not require ubiquitination, but are directly degraded by the 20S proteasome. 33, 34 Oxidation of proteins leads to destabilization of their tertiary structure, resulting in exposure of hydrophobic patches that are normally buried in the interior of the protein. It has been suggested that exposure of these hydrophobic sequences may trigger proteasomal degradation. 35, 36 It is tempting to speculate that methylation of arginine residues, which also increases the hydrophobicity of the protein surface, functions as a similar signal. The proteasomal machinery is very effective in cleaving proteins into peptides of approximately 3-22 amino acids in length, with a mean length of 6-9 residues. 37 Final degradation of these peptides into individual amino acids thus requires the adjunctive action of intracellular endo-and exopeptidases. Whether peptidases with specificity for methylated arginine residues exist remains to be established.
Degradation of ADMA by DDAH
Intracellular ADMA is metabolized to citrulline and dimethylamine, a reaction catalyzed by DDAH. 38, 39 Two isoforms of DDAH have been identified that are widely expressed in rat and human tissues. [40] [41] [42] A small part of ADMA is cleared by urinary excretion, but it has been estimated that more than 80% is metabolized by DDAH. 30 The very high K m value (Michaelis-Menten constant) of DDAH and its sensitivity to oxidative stress are two peculiar features of this enzyme that will be discussed in the following sections.
Kinetic properties of DDAH
There is abundant evidence that the activity of DDAH plays a critical role in regulating intracellular ADMA levels. On the one hand, impairment of DDAH activity, with subsequent elevated ADMA levels and reduced production of nitric oxide, can accelerate atherosclerosis. 43 On the other, ADMA acts as an endogenous inhibitor of angiogenesis, 44 and it has been shown that overexpression of DDAH may promote expression of vascular endothelial growth factor and induce tumor neovascularization. 45, 46 Apparently, because neither very high nor very low ADMA levels are desirable, ADMA concentrations must be kept between certain limits. The K m of DDAH of approximately 180 mol/l, 38 much higher than normal intracellular concentrations, may endow the enzyme with the properties to accomplish this task. It ensures that under normal conditions the enzyme works in the linear part of the substrate-velocity curve, which means that the rate of ADMA degradation is roughly proportional to its concentration. This is illustrated in Figure 3A , which shows that at low ADMA concentrations DDAH activity is also very low, leading to a rise in ADMA levels during rapid proteolysis. As the concentration of ADMA increases, DDAH activity also goes up, thereby preventing the accumulation of ADMA to very high levels. The high K m value of DDAH may thus provide buffering of ADMA concentrations, ensuring the presence of sufficient amounts of ADMA to allow its function as a regulator of NOS activity, while at the same time serving as a safety valve by rapidly degrading ADMA under conditions of excess supply.
DDAH and oxidative stress
DDAH is very sensitive to oxidative stress because the active site of the enzyme contains a critical sulfhydryl group that is required for its catalytic activity. 47 Consequently, pathologic stimuli that induce oxidative stress in endothelial cells, such as inflammatory cytokines, hyperhomocysteinemia, hyperglycemia, infectious agents and oxidized low-density lipoprotein (LDL), may reduce DDAH activity and allow ADMA to accumulate. [48] [49] [50] [51] [52] It is interesting to note that inhibition of endothelial NOS by elevated ADMA levels may lead to uncoupling of NOS, resulting in a shift from NO production to superoxide production. 53, 54 The fact that ADMA itself may induce oxidative stress suggests that under some pathologic conditions the DDAH-ADMA-NOS system may be precipitated into a vicious circle.
The effect of therapy with anti-oxidant vitamins on ADMA levels has not been studied thoroughly, but the results of two small studies suggest that vitamins C and E have no effect. 55, 56 In contrast, estrogens, which also have anti-oxidant properties, seem promising. Several in vitro and in vivo studies on the effect of estrogen on ADMA metabolism have been conducted. Exposure of human and murine endothelial cells to estradiol resulted in an increase in the activity of DDAH and was accompanied by a reduced release of ADMA. 57 Injection of rats with LDL increased serum levels of ADMA and reduced the endotheliumdependent relaxation of aortic rings. Both effects were attenuated by pretreatment with estradiol. 58 In addition, a negative association between ADMA and endogenous estrogen levels in women with coronary heart disease has been described. 59 We have studied the ADMA lowering effect of estrogens in the setting of hormone replacement therapy in postmenopausal women. 60,61 Both conjugated estrogen and estradiol reduced plasma ADMA concentrations to a similar extent, but the effect of estradiol was found to be strongly enhanced if administered in combination with the synthetic progestogen trimegestone. 60, 61 It is striking that this combination of hormones lowered not only ADMA but also arginine levels. It is tempting to speculate that arginine levels were reduced by an increased consumption of arginine by NOS, resulting from diminished inhibition of NOS by ADMA.
Role of amino acid transporters
Both the generation of free ADMA by proteolysis of methylated proteins and its degradation by DDAH are intracellular processes. Most of the ADMA is probably rapidly degraded in the cytosol of the same cell where it was made. However, a small part may escape degradation and leave the cell to enter the bloodstream. Transport of basic amino acids such as arginine, lysine and ornithine across the cell membrane is facilitated by functionally distinct transport systems, principally systems yϩ and yϩL. System yϩ belongs to a family of CAT that exclusively transports cationic amino acids, whereas system yϩL transports both cationic and neutral amino acids. 62 These transporters mediate the bidirectional transport of cationic amino acids, thus supporting important metabolic functions such as protein synthesis, NO production, polyamine biosynthesis, and interorgan amino acid flow. Arginine transport through both yϩ and yϩL systems is involved in NO synthesis in endothelial cells, 63 whereas arginine uptake by platelets is exclusively mediated by system yϩL. 64 Altered expression of CAT has been implicated in several clinical conditions, including congestive heart failure, chronic and acute renal failure, and septic shock. [65] [66] [67] It has been shown that system yϩ is capable of transporting both ADMA and SDMA across the cell membrane. 68 Changes in the expression of CAT may therefore not only influence the interorgan transport and cellular uptake of arginine, but also of ADMA and SDMA. In addition, both methylated arginines may compete with arginine for cellular uptake. It is interesting that both endothelial NOS and system yϩ are localized to caveolae in the plasma membrane. 69 This colocalization ensures an efficient supply of plasma arginine to NOS, but it may also provide plasma ADMA with direct access to NOS.
Metabolism of ADMA at organ level
Several studies have shown that ADMA accumulates in renal failure and is associated with cardiovascular mortality in end-stage renal disease. 2, 70 The human kidney is responsible for urinary excretion of both ADMA and SDMA but, in addition, the kidneys clear a substantial amount of ADMA by metabolic degradation, probably by DDAH. 71 Apparently, the kidney plays an important role in the metabolism of ADMA, but less information on the role of other organs in the clearance of ADMA is available. In recent years our group has studied the metabolism of both ADMA and SDMA at organ level in the rat. [72] [73] [74] In the experimental design, arteriovenous concentration differences and blood flow through the organ were measured, allowing the calculation of fractional extraction and net organ fluxes. Arteriovenous concentration differences were determined by a high-performance liquid chromatography method with high precision and sensitivity 75 and blood flow through individual organs was measured using radioactive microspheres. Data on renal and hepatic clearance of ADMA and SDMA in the rat are summarized in Figure 4 . Fractional extraction of ADMA (i.e. the percentage that is cleared from the plasma) is slightly higher in the kidney than in the liver ( Figure 4A ). However, because total plasma flow through the liver is higher than through the kidney, the liver clears more ADMA from the circulation than the kidney, as evidenced by the higher organ flux of the liver ( Figure 4B ). Comparable data for SDMA show that SDMA is cleared by the kidney, whereas extraction by the liver is negligible. It can be concluded that the liver plays an important role in the metabolism of ADMA by taking up large amounts from the systemic circulation. Endotoxemia, induced by the administration of lipopolysaccharide, resulted in a lower systemic ADMA concentration, in combination with a reduced uptake of ADMA by the kidney and an increased uptake by the liver. 73, 74 Mittermayer et al have studied the effect of endotoxemia on plasma ADMA levels in humans. No effect on ADMA or SDMA levels was observed, but a decreased arginine level and arginine/ADMA ratio were found. 76 The potential role of the liver in the metabolism of ADMA was already recognized in 1977 by Carnegie et al, who described increased urinary excretion of ADMA in patients with liver disease. 77 We have performed several clinical studies that confirm the essential role of the liver in the elimination of ADMA in humans. In patients undergoing major liver resection, ADMA levels were significantly elevated in a subgroup with prolonged postoperative hepatic injury. 78 In a prospective study in patients undergoing liver transplantation, preoperative ADMA concentrations were elevated, especially in those with chronic hepatic failure. 79 After transplantation, ADMA concentration decreased very rapidly but, in patients who experienced acute rejection, ADMA concentrations were higher during the first postoperative month compared with nonrejectors. These results are in line with reports by other investigators on elevated plasma levels of ADMA in patients with end-stage liver disease and alcoholic cirrhosis. 80, 81 In a population of critically ill patients with clinical evidence of dysfunction of two or more organs, plasma ADMA concentrations were elevated and significantly related to hepatic function. 82 Moreover, plasma ADMA concentration emerged as a strong and independent risk factor for mortality in these patients. Based on these findings we hypothesize that the accumulation of ADMA is a causative factor in the development of multiple organ failure by interfering with important physiological functions of NO production. 83 
Conclusions
The sequence of events leading to the generation of free ADMA (i.e. methylation of arginine residues by PRMTs and proteolysis) is not well characterized. Often, the formation of ADMA is regarded as an inevitable byproduct of protein turnover. This seems an oversimplification because both methylation and the breakdown of proteins are highly regulated processes. The crucial role of DDAH in the degradation of ADMA and its extreme sensitivity to oxidative stress are well documented. The bulk of ADMA is metabolized by DDAH, but this degradation may occur in a different cell or organ from the one in which ADMA is formed. CAT play an important role in trafficking of ADMA between cells and organs. The kidney and the liver play a significant role as sinks for excess ADMA. The interorgan transport of ADMA may have serious consequences in disease states. Overproduction or defective clearance of ADMA in a single organ may lead to its accumulation in other organs, thereby impairing their function.
